Impact of cancer in childhood, adolescence, and young adulthood on death, social security benefit uptake and education. A nationwide population-based cohort study by Ghaderi, Sara
Impact of cancer in childhood, 
adolescence, and young adulthood 
on death, social security benefit 
uptake and education 
A nationwide population-based cohort study  
Sara Ghaderi 
 
Dissertation for the degree philosophiae doctor (PhD)  
at the University of Bergen 
23 January 2014 
 2 
Sciencific environment 
 
The main scientific environment has been the Genetic Epidemiology research group at the 
Department of Global Public Health and Primary Care, University of Bergen, Norway. 
The current study was financed by the Norwegian Cancer Society. 
 
 
 
 
 
 
 
 
 
 3 
Acknowledgements 
I am deeply indebted to many people, whose support greatly improved my PhD work, 
to only some of whom it is possible to give particular mention here. 
I would like to acknowledge the Norwegian Cancer Society for financing the current 
study presented in this thesis. I would also like to thank the Department of Global 
Public Health and Primary Care where the PhD work was carried out.  
First and foremost, I wish to express my deepest gratitude to my excellent supervisor 
Tone Bjørge for her invaluable and professional help. I appreciate all her 
contributions of time, ideas, and funding to make my PhD experience productive and 
stimulating. Her constructive comments and guidance supported me throughout the 
entire PhD period. She kept reminding me that a PhD is a process, especially during 
stressful times. I am immensely grateful for the encouragement and the endless 
support she has given me.  
I would like to acknowledge my co-supervisor Dag Moster for his supervision during 
the completion of this PhD work. I highly appreciate the good discussions and 
comments as well as help with the data. 
I am especially grateful to Anders Engeland for the patient guidance, encouragements 
and advices he has provided throughout my work. Our fruitful discussions helped me 
to develop a better understanding of the topic. I appreciate his positive attitude and 
good sense of humour during the difficult times.  
I would like to thank my co-authors for their good and constructive comments on my 
work. I am in particular indebted to Astri Syse and Ellen Ruud for their important 
contributions to all the articles and sharing freely their knowledge and broad 
expertise. Especial thanks to Astri Syse for proofreading of the thesis within very 
short notice and her invaluable suggestions. I am also grateful to Maria Winther 
Gunnes for her great help and inputs which provided me with a better understanding 
of childhood cancer and its treatment.    
 4 
I am grateful to my colleagues in the Genetic Epidemiology Research Group for good 
discussions and an inspiring atmosphere. I am also thankful to Inger Haukenes and 
Michael Johnson Mahande for being so kind, helpful and sharing their experiences. I 
like to thank Ulrikke Johanne Hernæs, whom I shared office with during the last few 
months, for her friendship and cheerful attitude when I needed it most.    
At last but not least I would like to express my deepest appreciation to my dear 
family. My darling husband Mathias, thank you for your diligent proofreading and 
suggestions and more importantly your endless love, friendship and your great faith 
in me. My dear parents Abulkhair and Zahra, thanks for your unconditional love and 
the support you have given me. I am grateful for all the sacrifices you have made to 
help me fulfil my dreams. My dear brother Iman, thanks for your love and help 
whenever it was needed. In addition, I am grateful for your proofreading of the thesis 
and important suggestions and comments. My dear brothers Ali and Amir, and their 
significant others Wenche and Anne, thanks for your love and endless support. You 
believed in me when it was mostly needed and helped me rise and become who I am 
today.       
  
 5 
Contents 
 
SCIENCIFIC ENVIRONMENT ........................................................................................................ 2 
ACKNOWLEDGEMENTS ................................................................................................................. 3 
ABSTRACT .......................................................................................................................................... 8 
LIST OF PUBLICATIONS ............................................................................................................... 10 
ABBREVATIONS .............................................................................................................................. 11 
DEFINITIONS ................................................................................................................................... 12 
1. INTRODUCTION ................................................................................................................... 13 
1.1 BACKGROUND ....................................................................................................................... 13 
1.2 CANCER IN EARLY LIFE.......................................................................................................... 14 
1.2.1 Incidence .................................................................................................................... 14 
1.2.2 Mortality ..................................................................................................................... 15 
1.2.3 Cancer types ............................................................................................................... 18 
1.2.4 Treatment ................................................................................................................... 20 
1.2.5 Late effects ................................................................................................................. 21 
1.3 SOCIAL SECURITY BENEFITS .................................................................................................. 22 
1.3.1 Norway ....................................................................................................................... 22 
1.3.2 Social security benefits among cancer survivors ....................................................... 24 
1.4 EDUCATION ........................................................................................................................... 25 
1.4.1 Norway ....................................................................................................................... 25 
1.4.2 Educational achievements among cancer survivors .................................................. 28 
2. AIM OF THE THESIS ............................................................................................................ 30 
 6 
3. MATERIAL AND METHODS .............................................................................................. 31 
3.1 DATA SOURCES ..................................................................................................................... 31 
3.1.1 Norwegian Central Population Registry (NCPR) ...................................................... 31 
3.1.2 Cancer Registry of Norway (CRN) ............................................................................. 31 
3.1.3 Cause of Death Registry ............................................................................................. 32 
3.1.4 National Insurance Scheme (NIS) .............................................................................. 32 
3.1.5 Norwegian National Education Database (NNED) ................................................... 32 
3.2 STUDY POPULATION .............................................................................................................. 33 
3.3 STATISTICAL ANALYSIS ......................................................................................................... 35 
4. RESULTS ................................................................................................................................. 39 
4.1 PAPER I ................................................................................................................................. 39 
4.2 PAPER II ................................................................................................................................ 40 
4.3 PAPER III ............................................................................................................................... 41 
5. DISCUSSION ........................................................................................................................... 43 
5.1 METHODOLOGICAL CONSIDERATIONS ................................................................................... 43 
5.1.1 Study design ............................................................................................................... 43 
5.1.2 Internal validity .......................................................................................................... 44 
5.1.3 External validity ......................................................................................................... 46 
5.1.4 Precision .................................................................................................................... 47 
5.1.5 Choice of statistical methods ...................................................................................... 47 
5.1.6 Other methodological considerations ........................................................................ 48 
5.2 DISCUSSION OF RESULTS ....................................................................................................... 49 
5.2.1 Early mortality (paper I) ............................................................................................ 50 
 7 
5.2.2 Social security benefits (paper II) .............................................................................. 53 
5.2.3 Educational achievements (paper III) ........................................................................ 56 
6. CONCLUSION AND FUTURE PERSPECTIVE................................................................. 60 
REFERENCES ................................................................................................................................... 62 
ERRATA ............................................................................................................................................. 74 
APPENDIX I-III 
PAPER I-III 
 8 
Abstract 
 
Background: Improved survival for childhood and adolescent cancer patients due to 
advances in medical and supportive care is a great achievement of modern medicine. As 
the number of long-term survivors of cancer in childhood and adolescence is growing 
rapidly, increasing attention is being paid to the possible impact of the disease and its 
treatment on long-term health and social performance. Impact of cancer in childhood (0–
14 years), adolescence (15–19 years) and young adulthood (20–24 years) on early cancer 
death, uptake of social security benefits and educational attainment has been explored in a 
national cohort. 
Material and methods: All children born alive in Norway during 1965–1985 were 
identified by the Norwegian Central Population Registry and defined as the study cohort 
(approximately 1.2 million individuals). By linkage to the Cancer Registry of Norway, all 
children (N=2,481), adolescents (N=1,289) and young adults (N=2,032) diagnosed with 
cancer were identified. The cohort was followed from birth into adulthood by further 
linkage to compulsory national databases; the Cause of Death Registry, the National 
Insurance Scheme, and the Norwegian National Education Database. These registries 
include data on mortality, social security benefits, and education which were the main 
outcomes. Data were analysed by applying various regression models that allow for 
adjustment for confounders; Cox regression, logistic regression and competing risk 
model. Standardized incidence ratios were used in cases of rare outcomes.  
Results: Differences in overall mortality between the cancer patients and the cancer-free 
population decreased during our study period. Early cancer mortality (within 5-years after 
diagnosis) for all cancers also decreased since 1965. Overall, there were relatively fewer 
cancer-related deaths among female than male patients. Adolescents and young adult 
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patients had lower risk of cancer death than children in general, except for patients who 
were diagnosed with leukaemia (all combined).  
Overall, 5-year cancer survivors were 4.4 times more likely to receive any kind of social 
security benefits than the cancer-free population. Survivors from bone and connective/soft 
tissue tumours, central nervous system (CNS) tumours and leukaemia were most likely to 
be recipients of social security benefits. After neoplasms, the most common causes of 
receiving social security benefits were diseases of the nervous system, and injury and 
poisoning. 
In general, completion of education was lower among 5-year cancer survivors than the 
cancer-free population at all levels i.e. intermediate, under graduate and graduate 
education. Mainly survivors of CNS-tumours and those assumed to have received CNS-
directed therapy were at risk of educational deficits and experienced some delays in 
completion of an educational level. However, educational impairment diminished at 
higher levels of education, and consequently choice of educational fields was similar for 
the cancer survivors and the cancer-free population. 
Conclusions: More cancer patients become 5-year survivors today compared to earlier. 
These survivors are at increased risk of late effects. Medical surveillance and supportive 
care is therefore of high importance for the cancer survivors. Special attention should be 
paid to survivors of CNS-tumours, leukaemia and bone and connective/soft tissues 
tumours since they were at higher risk for late effects compared with other survivors. 
Careful follow-up of cancer survivors during their education is also recommended in 
order to maximize educational achievements.  
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Abbrevations 
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Definitions 
Early cancer death: Death which occurred within five years after a cancer diagnosis.  
Late effects: Occurrence of any medical condition of certain severity that qualified for 
uptake of social security benefits among the 5-year survivors. 
Childhood/children: Individuals aged 0–14 years. 
Adolescence/adolescents: Individuals aged 15–19 years. 
Young adulthood/adults: Individuals aged 20–24 years. 
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1. Introduction 
1.1 Background 
The incidence of childhood cancer has been studied worldwide. Reported findings are, 
however, not consistent. Different trends have been shown in different countries.1-4 Some 
studies report an increased incidence of childhood cancer, while other report a reduction, 
stable rates or no significant change.1-6 However, the cancer mortality in young 
individuals has shown a substantial decline in western countries during the past few 
decades.7, 8 Long-term survival after childhood cancers has improved dramatically over 
the last half century and about 75% to 80% become 5-year survivors with the current 
treatment regimens.9-11   
Risk factors for cancer among young people are in general unknown; however, certain 
genetic disorders as well as environmental factors have been shown to play a role.12, 13 
Studies have shown that congenital immune defects, fragile chromosomes (ataxia 
telangiectasia, Bloom syndrome, etc.), certain birth defects, high levels of ionizing 
radiation, race, ethnicity and infections are associated with an increased incidence of 
cancer.12, 14, 15  
Improved survival for childhood, adolescent and young adult cancer patients is one of the 
great achievements of modern medicine, and can be credited to advances in medical and 
supportive care based on research.16 As the number of long-term survivors is growing 
fairly rapidly, increased attention is being paid to the possible influences of cancer and its 
treatment on long-term health and social performance.17, 18 Morbidity, health status (e.g. 
subsequent neoplasms), fertility, social outcomes (future employments and marriage) and 
attained educational level are of particular concerns.19-26 The risk of specific health related 
outcomes and physical as well as psychological functioning vary considerably among the 
survivors.27-29 Health conditions may be influenced by characteristics of the individual, 
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the initial diagnosis or age at diagnosis.30 Health and welfare systems that are country or 
region specific may also play a role. 
1.2 Cancer in early life 
Cancer is rare in young ages compared to later in life; however, it is one of the most 
common causes of death in young people in developed countries.6, 31, 32 Types of cancers 
occurring in childhood, adolescence and young adults clearly differ from those 
developing in older adults.33  
 
1.2.1 Incidence  
In Europe, the overall incidence trends of cancer among children, adolescents and young 
adults varied in different countries over the last three decades.1-6 A report from Norway 
showed a stable cancer incidence rate for children since 1985.34 In developed countries, 
increases in childhood cancer (0–14 years) were observed for most tumour types35, 36 
while for adolescents and young adults (15–24 years), highest increases in incidence were 
observed for carcinoma, lymphoma, and germ-cell tumours.35, 37 Among children, 
incidence rates ranged from 130 (British Isles) to 160 cases (Northern Europe) per million 
while the corresponding value for those diagnosed between age 15–24 years was about 
200 per million6. Among children, the incidence rates are highest for leukaemia, central 
nervous system (CNS) tumours and lymphoma. Osteosarcoma and Ewing’s sarcoma 
present with the highest incidence in the age 15–19 years while gonadal germ cell 
tumours, and Hodgkin’s lymphoma peak at age 20–24 years.38  
In 2010, 128 cases of cancer among children below 15 years of age were diagnosed in 
Norway, and about 65 and 116 new cancer cases were diagnosed among adolescents (15–
19 years) and young adults (20–24 years), respectively.39  
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1.2.2 Mortality  
Although cancer mortality in young people has been substantially reduced in developed 
countries over the past few decades,7, 8, 40 it is still one of the most common causes of 
death in young people (Figure 1).  
 
Figure 1: Leading causes of death in Norway, 2011: Children, adolescents and young 
adults.41 
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Childhood cancer mortality (early and late mortality) from all neoplasms has been 
declining during the past few decades in the Nordic (Figure 2) and in most other 
European countries. However, higher rates of death were observed in Eastern Europe than 
in Western Europe and the United States (US).8, 31, 42 Highest 5-year survival was seen in 
Northern Europe (except Denmark) and Austria.43 Highest reduction in cancer mortality 
was observed for leukaemia and CNS-tumours among children9, 32 and Hodgkin 
lymphoma among adolescence and young adults.44 Despite the considerable reduction in 
cancer mortality, cancer continues nevertheless, to represent an important cause of death 
in young people (0–24) worldwide.31, 44 
In 2010, the cumulative risk of death in Norway caused by cancer among children, 
adolescents and young adults were 0.04% (0.02%), 0.02% (0.03%) and 0.02% (0.03%) 
among males (females), respectively.39  
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Figure 2: Overall cancer mortality rate per 100,000 for the Nordic counties.39 
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1.2.3 Cancer types 
Children 
Acute leukaemia is the most common cancer in children. In Norway, 35 to 40 children are 
diagnosed with acute leukaemia every year. Around 85% of these cases are acute 
lymphoid leukaemia (ALL) and 15% are acute myeloid leukaemia (AML).45, 46 Children 
diagnosed with ALL are typically between two to five years of age, while AML is most 
common in the first two years of life.45 
Brain tumours are the most common solid tumour in children. They can be seen through 
the entire childhood without any particular age peak.45 Among children, primary brain 
tumours are commonly located in the posterior cranial fossa. 
Lymphoma is another common cancer in young individuals. There are two major kinds of 
lymphomas, Hodgkin lymphoma (HL) and non-Hodgkin lymphomas (NHL). HL 
represent approximately 10% of all malignant lymphomas while all others are categorized 
under NHL.47 Other common cancer types among children are bone and soft tissue 
sarcomas, neuroblastoma, Wilms’ tumour, retinoblastoma, hepatic tumours and germ cell 
tumours.12 
 
Adolescents and young adults 
As the children grow older (after 15 years), they have distinctive medical characteristics 
which differ from younger children with cancer.33 Adolescents and young adults are also 
diagnosed with cancers more common among adults such as melanoma, testicular cancer, 
or ovarian cancer.  
The most common types of cancer in adolescents and young adults are lymphoma, 
leukaemia, brain and spinal cord neoplasms, soft tissue sarcoma, bone sarcoma, malignant 
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melanoma, germ cell tumours (including testicular and ovarian cancer), and thyroid 
cancer. Breast cancer also appears among young adults.33  
 
Differences between cancer in children, adolescents and young adults 
The distribution of cancer types differs between children, adolescents, and young 
adults.10, 48 Among children, NHL is more frequent than HL,2 however, mortality from 
NHL is higher among adolescents and young adults compared with children.49, 50 While 
tumours like gonadal germ cell tumours, osteosarcoma, Ewing’s sarcoma, and HL are 
most frequent in adolescents and young adults, these cancers occur less frequently in 
children. Vice versa, the most frequent fetal cancers are absent in adolescents and young 
adult, including the embryonal malignancies (Wilms’ tumour, neuroblastoma, 
medulloblastoma, ependymoma, hepataoblastoma, and retinoblastoma).38  
The type of soft-tissue sarcoma that occurs among adolescents differs from those 
occurring in younger children. Rhabdomyosarcoma accounts for more than 60% of soft-
tissue tumours occurring in children younger than 5 years of age, while it accounts only 
for 25% of cases among adolescents. It is shown that the risk of ALL decreases by age, 
accounting for only 6% of all cancers in adolescence. On the other hand, the incidence of 
NHL increases in older patients. The incidence of AML is similar in children and 
adolescents; however, it is more common in young adults.38   
Young people with cancer are likely to tolerate and respond better to cancer treatment and 
their bodies also tend to recover better than adults. However, receiving cancer treatment 
in young ages may cause a variety of late effects. 
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1.2.4 Treatment 
Norway has a public health care system where cancer treatment and follow-up is provided 
free of charge for the patients irrespective of social and economic status.51 Cancer 
treatment has gone through various changes during the past few decades. Generally, it 
may include surgery, radiation therapy and/or chemotherapy. For some frequent 
childhood tumours (i.e. brain tumours), the treatment and prognosis remain mainly 
unchanged, whereas for other cancers (i.e. leukaemia), there has been a dramatic increase 
in survival due to improved treatment regimens. These treatment regimens, however, 
come at a cost, with late effects manifesting later in adult life.28  
Treatment protocols are determined based on the type of cancer and the age of the 
patients.33 The general treatment trends described here, are based on the general 
knowledge of treatment protocols in Norway for young individuals at the given time 
periods. In Norway, all children with cancer receive their diagnosis and treatment plan at 
one of four (previously five) centres.11 The treatment for various cancers has been 
nationally agreed upon, which secures equal access to identical treatment regardless of 
geographic location. Since the mid-1980s, there have been common treatment protocols 
for children with leukaemia across the five Nordic countries. Since the compliance to 
these national standards has been high, it was possible to make assumptions of treatment 
types applied. For adolescents and young adults the structure of cancer treatment has been 
more de-centralized which make the assumptions regarding treatment in this age group 
somewhat more uncertain.52 
Treatment protocols for CNS-tumours differ from the treatment protocols applied for 
other cancers. CNS-tumour treatment is determined based on morphology, localization of 
the tumour and the age of the patient. The treatment protocol may consist of one or 
several modalities including surgery, radiation and chemotherapy.53  
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In the 1970s and early 1980s, more patients with leukaemia received prophylactic CNS-
directed therapy in the form of radiation than what is currently the standard for leukaemia 
treatment. In Norway, the current treatment does not include CNS radiation. This was 
replaced by intrathecal chemotherapy as well as high-dose chemotherapy with penetrance 
to the CNS as early as the mid-1970s. Since the mid-1980s, only a very small group of 
patients have received prophylactic cranial irradiation which is no longer part of the 
general leukaemia treatment regimen (except for relapses). Intrathecal chemotherapy is 
kept as an essential part of leukaemia treatment regimens in order to reduce the rate of 
CNS relapses. Similar to leukaemia patients, CNS-prophylactic therapy (in form of 
intrathecal chemotherapy) was generally administered for patients with NHL. However, 
use of cranial irradiation substantially decreased since the early 1980s together with 
optimized chemotherapy regimens.54, 55  
 
1.2.5 Late effects  
Due to advances in childhood cancer treatment during the past few decades, today about 
75% to 80% of the cancer patients will become 5-year survivors.10, 34 Studies have shown 
that long-term cancer survivors have higher risk of late morbidities, chronic diseases and 
late mortalities compared with the control groups.18, 56-59 According to previous studies, 
chronic health problems and a severe or life-threatening condition were reported for more 
than 50% and 25% of the childhood cancer survivors, respectively.18, 30, 60, 61 The late 
effects are due to the specific cancer types, cancer treatment protocols (especially 
radiation therapy), age at diagnosis or subsequent neoplasms.30, 61-67 Among late effects 
affecting childhood cancer survivors, second malignant neoplasms, defects of vision, 
hearing loss, endocrine and metabolic problems, musculoskeletal abnormalities, activity 
limitations, dental abnormalities, osteoporosis, chronic fatigue, psychosocial problems, 
obesity, reduced fertility, mental disorders, decline in intelligence and 
cardiovascular/pulmonary deaths have been reported frequently.12, 18, 24, 30, 63-66, 68-72 
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Poorer quality of life among cancer survivors has been reported in some studies while 
others showed minor or no differences.73, 74 A cross-sectional study on survivors of ALL 
showed that survivors who received higher dosage of cranial radiotherapy (24 Gy) 
showed impairments in immediate and delayed memory compared with those who 
received lower dosages (18 Gy).75  
 
1.3 Social security benefits 
1.3.1 Norway  
To receive social security benefits, an individual should fulfil certain criteria. These 
criteria are based on health conditions of the individuals and the financial burden caused 
by such health conditions, irrespective of the general wealth of the individual. The only 
mandatory condition to be qualified to receive social security benefits is legal residence in 
Norway for the last 12 months. In case of disability pension, an individual must have been 
a member of the National Insurance Scheme (NIS) three years prior to the occurrence of 
disability. An individual may receive more than one benefit due to various health related 
issues. The duration of benefits varies according to need which is decided by medical 
personnel together with representatives from the NIS.76 In 2012, the uptake of basic 
benefits, attendance benefits and disability pensions among the entire population in 
Norway was 2.5%, 1.7% and 9.7% (age 18–66 years), respectively.76 The corresponding 
value for uptake of medical rehabilitation benefits was 1.0%. Statistics on uptake of 
medical rehabilitation benefits was only available until June 2009 since it was replaced 
with another benefit from 2010 (work assessment allowance (WAA)).77 
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Basic and attendance benefits 
Basic benefits are awarded to cover (in full or in part) additional expenses as a result of 
illness, injury or congenital defects and disabilities (bodily defects). These additional 
expenses may include for instance costs to cover support bandages, running and/or 
operating technical aids, transport, or a guide dog. Attendance benefit is granted in case of 
special need for care and supervision as a result of illness, injury or congenital disabilities. 
This include the need for extra nursing or special care, training, help with getting 
up/going to bed, eating and personal hygiene.20, 78 When the need for assistance is being 
considered, the need for stimulation, education and exercise at home will also be 
evaluated.76 There are no age limits for receiving basic or attendance benefits.  
 
Medical rehabilitation benefits and disability pension 
The purpose of medical rehabilitation benefits (part of WAA since march 2010)77 and 
disability pensions79 is to provide subsistence allowance to persons who are between 18–
67 years and have permanently impaired earning capacity due to illness or injury. The 
mandatory condition is that a person must have been a member of the NIS during the last 
three years up until the disability. The medical rehabilitation benefits are relatively short-
term and provides up to 66% of yearly income for the period that one is under active 
treatment with the aim to improve one’s working capacity.76 Disability pensions can only 
be considered after appropriate rehabilitation, and the earning capacity must be reduced 
by at least 50%. In case of occupational injury, 30% reduction in earning capacity is 
sufficient.  
 
 24 
1.3.2 Social security benefits among cancer survivors  
An association between loss of working ability and cancer and its treatment has been 
reported from a Norwegian study on cancer survivors diagnosed before age 15. The effect 
was particularly marked among CNS-tumour survivors.20 Another Norwegian study on 
the need for rehabilitation services among cancer patients showed that approximately 
63% of the survivors were in need of at least one kind of rehabilitation service such as 
physical therapy, psychological counselling, consultations with social workers, and 
occupational therapy. The authors also reported that 40% of the patients who were in need 
of rehabilitation services did not receive such services.80 
Individuals who were young at time of diagnosis (before school age), and survivors of 
brain tumours, leukaemia, lymphoma and other solid tumours were more likely to receive 
disability pension.81 Lower social and psychosexual development was also reported 
among recipients of disability pensions.82 
A general lack of knowledge about legislation of health insurance among cancer survivors 
was reported by a US study interviewing 5-year cancer survivors diagnosed before age 
21.83 Despite often high costs, it was shown that survivors were grateful to have any 
insurance coverage. Increased insurance costs were of major concern among the 
survivors. Those who were not insured had a general concern about the inability to get 
required preventive care.    
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1.4 Education  
1.4.1 Norway 
Similar to the health care system, all public education in Norway is free of charge and 
equally available to all individuals. At schools, educational plans are generally adapted to 
each pupil’s abilities. Pupils who are not able to achieve learning yields from the ordinary 
teaching and are in need of special education are entitled to receive such services, either 
within ordinary schools or in special education settings outside ordinary schools.84    
Currently, the levels of education are structured in three main levels, compulsory 
education (1 to 10 years of education), intermediate education (11 to 14 years of 
education) and tertiary education (14 to 20 years of education) (Figure 3).  
 
Figure 3: Current classification of education.85 
 
 However, the educational system has undergone structural changes during the past few 
decades. The law in 1959 made seven years schooling mandatory. In 1969, primary and 
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compulsory education was extended to nine years. Further, the Norwegian education 
system has undergone a number of extensive reforms during the past decades; Reform 94, 
Reform 97 and Quality Reform of 2003. A reform of secondary education, termed 
‘Reform 94’, gave rights to three years of secondary education. With the ‘Reform 97’, the 
curriculum was extended and primary school became 10 years.51, 86 Unlike Reform 94 and 
Reform 97, the ‘Quality Reform of 2003’ mainly affected the structure of tertiary 
education in Norway. Therefore, the number of years at each level has increased by 
approximately one to two years over the last 30 years. 
The compulsory education consists of two main stages, primary school (class level 1–7) 
and lower secondary school (class level 8–10). Those who completed compulsory 
education or equivalent, have right to upper secondary education which leads to 
admission to higher education, vocational qualifications or to basic skills.84 Pupils who 
choose vocational education should take a supplementary programme for general 
university admission certification to qualify for admission to universities and university 
colleges. Upper secondary education normally takes three years. Vocational education 
and training mainly leads to a craft while general studies lead to general university 
admissions certification.  
Tertiary education is built on completed three years of upper secondary education. It 
consists of a three to four-years bachelor degree (under graduate education), a subsequent 
two-year master degree (graduate education) and a three-year doctorate degree 
(postgraduate education). There are eight broad fields of education available at the higher 
level of education (Figure 4). Broad fields of education are classified according to the 
academic content of the various educational activities and each field comprises programs 
that are as academically homogenous as possible.87  
The State Educational Loan Fund provides financial support for educational purposes in 
the form of loans and grants which aims to minimize the impact of parental income on 
students’ choices of education. Students in programs for both general and vocational 
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studies and higher education are entitled to receive such economic support which is made 
available for everyone regardless of their social and economic background.87 
 
Figure 4: General classification of the academic content at the under graduate and 
graduate levels (see Appendix I for more information).85 
 
Special education is considered when pupils are unable to obtain a satisfactory learning 
outcome from teaching services provided at schools due to mobility, visual and hearing 
impairments, physical disabilities, speaking and communication difficulties, as well as 
brain injuries. The right for special education is granted based on expert assessment 
carried out by the educational and psychological counselling in the local or regional 
authority. This evaluation is furthermore used to reach an individual decision on special 
need education. An individual education plan is then provided for pupils in primary or 
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secondary education which includes goals and contents of the special education. The 
educational plan is mandated to be evaluated every six months.88  
  
1.4.2 Educational achievements among cancer survivors 
Cancer treatment may influence the social development and academic progress of the 
survivors. In general, gender, treatment with cranial irradiation, age at diagnosis, cancer 
site, year of diagnosis and parental educational level has been reported to influence 
educational achievements.19, 25, 89-92  
Nordic studies have reported that mostly survivors of CNS-tumour experienced reduced 
educational achievements91, 93 and that poor academic achievements is likely to affect the 
chances of finding desirable occupation and reach economical goals.94 Finnish studies on 
leukaemia and brain tumour survivors showed that school grades were mostly affected in 
foreign language studies. They suggested this to be an indication of diminished verbal 
learning among this group of survivors.91, 95 Lower school grades were reported in 
patients with NHL, while similar or better grades were observed among patients with HL. 
Wilms’ tumour patients had similar grades compared to their controls, except for physical 
education.19 
A study by Lancashire et al. based on the British Childhood Cancer Survivor Study 
showed that survivors of bone sarcoma and retinoblastoma were more likely to obtain at 
least one O’level (equivalent to the Norwegian compulsory education; 1 to 10 years of 
education) compared to the general population.89  
Cancer survivors were more likely to repeat a grade and had more often school absences 
in a study from the US compared to their control group.92, 96 Female survivors were 
reported to be less frequently finished with high-school and/or achieved an advanced 
university degree in a Dutch study.25 The rate of college graduations was shown to be 
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lower among survivors of childhood and young adult AML compared to their siblings in 
the Childhood Cancer Survivor Study. On the other hand, both survivors and their 
siblings had higher college graduation than the general population.60  
Increased needs of special education services among cancer survivors compared to their 
siblings have been reported.27 A study from the US on 5-year cancer survivors diagnosed 
before age 21, reported an increased need for special education services among survivors 
diagnosed before age 6, and diagnosed with a leukaemia, brain tumours or Hodgkin’s 
disease relative to their siblings.97  
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2. Aim of the thesis  
The overall aim of this thesis was to assess the impact of cancer in young age (0–24 
years) on death, uptake of social security benefits and educational attainment. 
The specific aims were to examine: 
x Changes in overall and cancer specific early death during the past 40 years among 
children, adolescents and young adults with cancer born during 1965–1985 
(paper I). 
x Uptake of social security benefits among survivors of cancers in young ages 
compared to the cancer-free population (paper II). 
x Educational attainment and choice of educational fields among long-term survivors 
of cancer in childhood and adolescence compared to the cancer-free population 
(paper III). 
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3. Material and methods 
3.1 Data sources 
3.1.1 Norwegian Central Population Registry (NCPR) 
The NCPR provides unique 11-digit personal identification numbers (PIN) for individuals 
in Norway at birth or immigration since 1960. Furthermore, the NCPR registers 
demographic information on the entire population in Norway based on these PINs. 
Information such as date of birth, place of residence and date of emigration or death are 
gathered in the NCPR.98 Origins of immigrants are also included. 
 
3.1.2 Cancer Registry of Norway (CRN) 
All information about cancer cases occurring in Norway has been reported to the CRN 
since 1953. Pathological and clinical notifications, and death certificates are the main 
reporting sources. Information about site, histological type and stage of disease at the time 
of diagnosis are extracted from these sources.48 Registration of topography was based on 
a modified version of International Classification of Diseases (ICD-7)99 until 1992, and 
ICD-O-2 has been the basis for coding from 1993 onwards. Tumour morphology was 
coded according to the Manual of Tumor Nomenclature and Coding through 1992 and 
ICD-O morphology codes were adopted from 1993. Non-solid tumours have been coded 
according to a separate coding systems from 1986.48 
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3.1.3 Cause of Death Registry 
In Norway, providing official statistics on causes of death has been obligatory since 1951 
onwards. Such statistics include the entire population in Norway at the time of death 
irrespective of place of death (in Norway or abroad). Statistics on causes of death are 
prepared on the basis of medical death certificates by public health officers. Causes of 
death were registered according to ICD-8 during 1969–1985, ICD-9 during 1986–1995, 
and ICD-10 from 1996 onwards.100 
 
3.1.4 National Insurance Scheme (NIS)  
All individuals residing in Norway are insured by the NIS irrespective of their nationality 
or employment status.101 Disability benefits are provided by NIS for people whose health 
conditions are of sufficient severity to be an economic burden. NIS provides for instance 
attendance benefits, basic benefits, disability pensions and medical rehabilitation benefits 
(replaced with WAA since 2010).76 The dates at which the benefits were granted and 
diagnoses associated with the benefits are recorded. Diagnoses are based on medical 
examinations and are classified according to ICD-9 and -10. NIS began electronic 
registration of social security benefit records in 1992. The registration included both 
already existing and new benefits.  
 
3.1.5 Norwegian National Education Database (NNED) 
Since 1970, all individual-level based statistics on education – from completed lower 
secondary education to tertiary education including doctoral studies – have been gathered 
in NNED.87 All information on educational attainment is reported from respective 
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institutions to NNED annually.84 Fields of education are coded based on the Norwegian 
Standard Classification of Education (a 6-digit coding system).  
 
3.2 Study population 
This project is based on a population-based cohort. All children born alive in Norway 
during 1965–1985 (1,216,058 individuals) were identified by the NCPR and defined as 
our study cohort (625,349 males and 590,709 females). All individuals (both with and 
without cancer) were followed up into adulthood until they were between 24 and 44 years 
of age by linkage through the PIN to abovementioned national registries.  
All cancer cases were identified by linkage to the CRN and were further grouped as 
children (0–14 years), adolescents (15–19 years) and young adults (20–24 years) based on 
age at diagnosis – a total of 5,802 individuals (paper I). Only the first cancer diagnosis 
was considered. Furthermore, all 5-year cancer survivors (4,031) were included in 
paper II and paper III (Figure 5).   
 
 34 
 
Figure 5: Establishment and follow-up of the study cohort. The comparison group in all 
three papers were the cancer-free population. 
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The cohort was followed by linking compulsory national registries, using the 
aforementioned unique 11-digit PIN assigned to all individuals living in Norway after 
1960. A summary of follow-up time for papers I–III are presented in Table 1. 
Table 1: Follow-up time of the cancer individuals 
 Start of follow-up  
(whichever occurred last) 
End of follow-up  
(whichever occurred first) 
Paper I x Birth x Five years after diagnosis 
x Death 
x Emigration 
x 31.12.2009 
Paper II a  x Five years after diagnosis 
x 01.01.1992 
x Uptake of social security benefit 
x Death 
x Emigration 
x 31.12.2006 
Paper III b x Ages 17c, 20d, 23e 
x Five years after diagnosis 
x Attainment of education in 
question 
x Death 
x Emigration 
x 31.12.2009 
a The follow-up time for those who received medical rehabilitation benefits were 2002–2007; b Individuals 
diagnosed with cancer after start of follow-up were censored; c For intermediate education; d For under 
graduate education; e For graduate education.  
 
3.3 Statistical analysis  
To estimate the risk of death (total death) among the cancer patients relative to the 
cancer-free population (general population), a time-varying Cox regression model with 
age as the time variable and cancer as a time-varying variable was applied to the entire 
cohort.102 A competing risk model103 with time from diagnosis as the time variable was 
applied including only the cancer patients and was used for the estimation of cancer death 
sub-hazard ratios (SHR).104, 105 SHR is defined as ratios of hazards related to cumulative 
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incidence in the presence and absence of the risk factor.106 The primary outcome was 
defined as death from cancer. Death from a non-cancer cause was considered a competing 
event (paper I). A description of variables used is presented in Table 2.  
Standardized incidence ratios (SIR) were used to describe the prevalence of diseases 
extracted from NIS. SIR was used to show the occurrence of a specific disease among the 
5-year cancer survivors relative to the occurrence of the same disease in the cancer-free 
population; diseases were identified through social security benefits uptake. The person 
times were calculated for the years 1992–2006 for all outcomes except for medical 
rehabilitation benefits for which the person-times were available from 2002 to 2007. 
Diagnoses retrieved from NIS were coded according to the ICD-10 coding system and 
were categorized into main diagnostic groups (paper II).  
Cox regression models with time from enrolment until attainment of a given educational 
level as the time variable was applied in paper III. Cox regression was used to estimate 
the hazard ratio (HR) with 95% confidence interval (CI) of educational attainment among 
the cancer survivors compared with the cancer-free population. Logistic regression 
models were used to compare the choice of various educational fields at higher levels of 
education; odds ratios (OR) with 95% CIs were calculated. Covariates included in the 
model are shown in Table 2. 
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Table 2: Overview of the outcomes, statistical models and variables used in this study 
Paper I Paper II Paper III 
Main outcome 
x Early mortality Uptake of  
x Attendance benefits 
x Basic benefits 
x Disability pension 
x Medical rehabilitation 
benefits  
x Educational attainment  
x Choice of educational fields 
Statistical model 
x Time-varying Cox 
regression  
x Competing risk  
x Standardized 
incidence ratio 
x Cox regression 
x Logistic regression  
Covariates 
Time-varying Cox regression 
x Year of diagnosis   
o 1965–1974 
o 1975–1984 
o 1985–1994 
o 1995–2004 
o 2005–2009 
Competing risk  
x Cancers (ICD-7) 
o CNS-tumours 
o Bone and 
connective/soft 
tissue tumours 
o Lymphoma  
o Leukaemia*  
x Age at diagnosis  
o 0–14 
o 15–19  
o 20–24  
x Year of diagnosis  
o 1965–1974 
o 1975–1984 
o 1985–1994 
o 1995–2004 
 
 
x Age  
o 5–9 
o 10–14 
o 15–19 
o 20–24 
o 25–29 
o 30–34 
o 35–39 
o 40–44  
x Calendar periods  
o 1970–1974 
o 1975–1984 
o 1985–1994 
o 1995–2004 
o 2005–2009 
x Gender 
 
 
x Age at diagnosis  
o Intermediate level 
 0–4 
 5–9 
 10–12 
o Under graduate level 
 0–4 
 5–9 
 0–14  
o Graduate level  
 0–4 
 5–9 
 10–14 
 15–18  
x Year of diagnosis 
o 1965–1974 
o 1975–1984 
o 1985–1994 
o 1995–2004 
x Cancer survivors 
o CNS-tumours  
o CNS-directed 
therapy 
o All other survivors  
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o 2005–2009 
x Gender 
Adjusted for Stratified by Adjusted for 
Time-varying Cox regression 
x Gender 
x year of birth  
o 1965−1969 
o 1970−1974 
o 1975−1979  
o 1980−1985 
x Year of birth  
o 1965–1969 
o 1970–1974 
o 1975–1989 
o 1980–1985  
x Age at diagnosis 
o 0–14 
o 15–19 
o 20–24 
x Year of diagnosis 
o 1965–1974 
o 1975–1984 
o 1985–1994 
o 1995–2004 
o 2005–2009 
x Cancers 
o CNS-tumours 
o Bone and 
connective/soft 
tissue tumours 
o Lymphoma  
o Leukaemia  
x Gender 
x Parental education 
o No education 
o Compulsory  
o Intermediate 
o Tertiary 
x Gender 
x Year of birth  
o 1965–1969 
o 1970–1974 
o 1975–1989 
o 1980–1985 
Statistical software 
x PASW Statistics 18 
x STATA/IC 11 
x PASW Statistics 18 x PASW Statistics 18 
* Additionally, ALL and AML were considered separately. 
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4. Results 
4.1 Paper I 
The study included 3,268 males and 2,534 females diagnosed with cancer. The mean age 
at diagnosis for both genders was 14.7 (range 0–25 years). The mean age of children at 
death was 7.0 years for males and 6.9 for females. The mean ages among adolescents and 
young adults for both genders were 19.0 and 24.1 years, respectively. 
In general, cancer occurred more frequently among males than females. The most 
frequent cancers among children were leukaemia and CNS-tumours. Cancers of the testis 
and lymphoma were most common among male patients older than 15 years, while 
malignant melanoma and lymphoma were most frequent among female patients. 
Leukaemia was the most common cause of death. The percentage of cancer deaths 
occurring among male patients was higher than among females. Among children, death 
from CNS-tumours and leukaemia (also when ALL was considered separately) showed 
the largest decline during our study period. Among adolescents, deaths from cancer of 
bone and connective/soft tissue tumours, lymphoma and AML were most pronouncedly 
reduced. Despite the substantial reductions in mortality among children and adolescents, 
the risks of cancer death among young adults were reduced moderately in the past 40 
years. 
The entire study cohort (time-varying Cox regression)  
To study the risk of early death, patients were followed for an average of 4.1 years (range 
0–5 years). A total of 1,499 patients died within five years after diagnosis. Cancer was the 
cause of death in 94% of these patients. Overall HR of death for the cancer patients 
relative to the cancer-free population decreased from 361.5 (95% CI: 313.9–416.2) in 
1965–1974 to 19.3 (95% CI: 9.2–40.7) in 2005–2009.  
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The cancer patients (competing risk) 
When all cancer sites were studied combined, the competing risk model showed fewer 
cancer related deaths among female compared with male patients (SHR: 0.83; 95% CI: 
0.75–0.93). Lower mortality was observed among adolescents and young adults. 
Except for leukaemia (also when ALL was considered separately), adolescents and young 
adults had lower mortality than children. Furthermore, adolescents with AML had higher 
mortality than children (SHR: 1.36; 95% CI: 0.81–2.26); but this difference was not 
statistically significant.    
 
4.2 Paper II 
A total of 4,031 individuals were 5-year cancer survivors (55.4% males). Cancer 
survivors and the cancer-free population were followed for an average of 13.2 (range 0–
39.3) and 34.2 (range 0–45) years, respectively.  
Uptake of social security benefits increased with younger age at diagnosis, year of birth 
and year of primary cancer diagnosis. In total, survivors of bone and connective/soft 
tissue tumours (SIR: 10.8; 95% CI: 9.1–12.9), CNS-tumours (SIR: 7.7; 95% CI: 6.9–8.6) 
and leukaemia (SIR: 6.1; 95% CI: 5.3–7.0) had the highest risks of late effects as 
indicated by uptake of social security benefits.  
After extracting diagnoses from the NIS, a total of 29.7% of the survivors were shown to 
be recipients of social security benefits compared to 10.8% of the cancer-free population. 
Among the cancer survivors, 9.1% received attendance benefits, 11.0% received basic 
benefits, 8.4% received disability pensions and 10.1% received medical rehabilitation 
benefits. The corresponding percentages among the cancer-free population were 1.1%, 
2.2%, 2.2% and 7.5%, respectively. Uptake of benefits among the cancer survivors 
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overall was 4.4 times (95% CI: 4.1–4.6) higher than that of the cancer-free population (all 
social security benefits combined). The overall SIR for receiving attendance benefit was 
17.9 (95% CI: 16.3–20.0) and 9.3 (95% CI: 8.5–10.3) for uptake of basic benefits. The 
overall SIR for uptake of disability pension was 5.6 (95% CI: 5.0–6.2) while it was 1.3 
(95% CI: 1.1–1.4) for receiving medical rehabilitation benefits.   
Neoplasm was the main cause of social security benefit uptake. Among survivors, after 
neoplasm, injury and poisoning and diseases of the sense organs were the most common 
causes of attendance and basic benefits uptake. Disability pension were commonly 
granted for endocrine, nutritional and metabolic and immunity disorders and diseases of 
the nervous system. Diseases of the genitourinary system and infectious and parasitic 
diseases were the main causes for uptake of medical rehabilitation benefit. 
 
4.3 Paper III 
A lower proportion of the cancer survivors completed intermediate (67%), under graduate 
(31%) and graduate education (7%) compared with the cancer-free population (70%, 
35%, and 9%, respectively). Among the cancer survivors, a higher proportion of females 
completed their education when compared to their male counterparts.  
Intermediate level  
Educational deficit was observed among survivors of CNS-tumours diagnosed during 
1975–1984 (HR: 0.6; 95% CI: 0.4–0.7) and 1985–1994 (HR: 0.6; 95% CI: 0.4–0.7). 
Survivors of CNS-tumours diagnosed at ages 0–4 (HR: 0.4; 95% CI: 0.3–0.6) and 5–9 
years (HR: 0.6; 95% CI: 0.5–0.8) displayed significant educational impairment.  
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Under graduate level 
Survivors of CNS-tumours who were diagnosed during 1975–1984 (HR: 0.5; 95% CI: 
0.3–0.7) and 1985–1994 (HR: 0.5; 95% CI: 0.3–0.7) showed a significant educational 
deficit. Significantly lower educational attainments were seen at all ages of diagnosis. 
Among survivors who were assumed to receive CNS-directed therapy, completing under 
graduate education was lowest in survivors who were diagnosed during 1975–1984 (HR: 
0.7; 95% CI: 0.6–0.9). Survivors diagnosed at ages 0–4 (HR: 0.7; 95% CI: 0.6–0.9) and 
10–14 years (HR: 0.6; 95% CI: 0.4–0.8) also demonstrated educational deficits.  
“Natural science, vocational and technical subjects” was the most common field of 
education among male individuals. Among females (both the survivors and the cancer-
free population), “Health, welfare and sport” was most frequently studied. Female 
survivors who received CNS-directed therapy chose the field of “Health, welfare and 
sport” more frequently than females in the cancer-free population (OR: 1.8; 95% CI: 1.1–
2.8).  
Graduate level 
Survivors of CNS-tumours were less likely to complete graduate education compared 
with the cancer-free population (male: OR: 0.5; 95% CI: 0.3–0.9; female: OR: 0.4; 95% 
CI: 0.2–0.8). Completing graduate level was also less frequently observed among male 
survivors assumed to receive CNS-directed therapy (OR: 0.5; 95% CI: 0.3–0.8).  
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5. Discussion 
5.1 Methodological considerations 
5.1.1 Study design  
All three studies have a prospective cohort design. The cohorts used in these studies were 
based on a linkage of comprehensive registries with reliable and compulsory 
information.107-112 Norway has had a relatively stable population where emigration rates 
have been minor. The entire population is traced by national registries and statuses of 
emigration, immigration or deaths are recorded accordingly.41  
A case-control study or a prospective hospital-based study as alternative designs would 
probably provide more detailed information about each individual and in particular about 
treatment regimens encountered. The size of the study population would, however, be 
considerably smaller. As the outcomes studied are relatively rare (e.g. uptake of certain 
social security benefits) such designs would be difficult to implement. Furthermore, there 
would be concerns about the existence of possible biases (in particular information and 
selection biases). The advantage with a registry-based cohort design113 is the large 
population size where the registered information for each individual is almost complete 
(even though not very detailed) and misclassifications are likely to be non-differential 
between the cancer survivors and the cancer-free population. Therefore, the cohort design 
was appropriate for the aims of the current thesis.  
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5.1.2 Internal validity 
Internal validity refers, in this instance, to the correct measurement of the outcome in 
question (Figure 6). Internal validity may be reduced by the presence of systematic errors 
which may include selection bias, information bias and confounding.114  
 
Figure 6: Validity of a study 
 
Selection bias occurs if individuals in exposed and unexposed groups are not truly 
comparable.114 One possible cause of selection bias in a cohort study is loss to follow-up. 
The current study is based on data from registries which are compulsory and selective 
reporting is minimal. Our study population included the entire population in Norway born 
alive during 1965–1985 and the comparison group is the entire cancer-free population. 
The total loss to follow-up was approximately 0.2%. Such a minor percentage is unlikely 
to cause any serious selection bias, and it thus assumed not to have influenced the results 
of the present research. 
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Recall bias and reporting bias are two forms of information bias.114 Recall bias is a 
systematic error initiated by differences in the accuracy or completeness of the memory 
recollections reported by study participants regarding an event. Reporting bias is defined 
as selective revealing or suppression of information by individuals. Occurrences of such 
biases in the present study are unlikely since the information were collected from 
registries/databases with compulsory reporting. 
Confounding implies that the effect of the exposure of interest is mixed together with the 
effect of another variable.114 For confounding to be present, the confounding variable 
must be associated both with the exposure and the outcome.  
In paper I, the time-varying Cox regression was adjusted for gender and year of birth 
(Table 2). Cancer mortality differed between genders while year of birth could mirror 
changes in cancer treatment to some degrees.  
In paper II, late effects among the cancer survivors were considered in 5-year age-groups 
(Table 2) since age at diagnosis has been shown to have a pronounced impact on 
occurrence of late effects.30 Cancer treatment protocols have undergone significant 
changes over time, especially at the beginning of our study period. Therefore, we 
considered the year of diagnosis also as a potential confounder.   
In paper III, analyses were adjusted for gender, year of birth, and the highest registered 
attained level of the parents’ education (Table 2). It has been shown that gender plays an 
important role in the educational achievements of cancer survivors.91 Year of birth was 
considered a potential confounder since the educational system has undergone rather 
radical changes during the study period. Parental level of education has been shown to 
have a considerable effect on the educational achievement of their offspring.90, 115 In our 
study, parental education did not influence the relation between cancer and educational 
achievement. This is not surprising due to the characteristic of cancer in early ages where 
causes are mainly unknown. Thus, distribution of individuals with cancer generally varies 
little across parents’ socioeconomic status and educational attainment. As opposed to this, 
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many adult cancer forms, such as for instance cervical and lung cancer, are associated 
with socioeconomic status (e.g. educational level).116-118 Nevertheless, inclusion of 
parental education in our analysis helped the comparability with results from other 
studies. 
 
5.1.3 External validity 
External validity is the extent to which the results can be generalized to other 
settings (Figure 6).114 
Health care, welfare and educational systems vary significantly between countries. This 
could affect the generalizability of our results. In paper I, difference in risk of death 
(overall and cancer specific) between the cancer patients and the cancer-free population 
has been reduced over time. This result is similar to those observed in other studies from 
developed countries.3, 8 Hence, the results from paper I could be generalized to countries 
with similar health care systems and cancer treatment protocols. 
In paper II, higher rates of social security benefits uptake was observed among cancer 
survivors compared with cancer-free individuals. Social security systems are highly 
country specific. Thus, the results from paper II could only be generalized to countries 
with similar social and welfare systems such as the other Nordic countries.  
In paper III, some educational deficit was observed among the cancer survivors compared 
with the cancer-free population (especially survivors of CNS-tumours and those assumed 
to have received CNS-directed therapy). Education in Norway is free of charge, and 
consequently our results cannot be generalized to countries with educational systems 
different from Norway.   
Health care systems differ across countries. Furthermore, the health status and prevalence 
of other diseases in children, adolescence and young adults may also vary across 
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countries, both as a result of health care system differences but also due to differences in 
welfare levels and/or other factors important for general health.119 Hence, the results from 
all three papers could be generalized to countries with similar health care systems and 
cancer treatment protocols specifically, as well as similar distributions of other diseases 
and health and welfare measures in general. 
 
5.1.4 Precision 
Precision refers to the absence of random errors.114 A large study sample ensures high 
precision. In this study, the large population that is retrieved from reliable registries leads 
to a high precision of the estimates obtained in all three papers. On the other hand, the 
number of cancer cases and the number of outcomes for the cancer individuals were 
relatively small. In order to further increase the sample size of cancer individuals, pooling 
data from similar registries in the Nordic countries is an option.120  
 
5.1.5 Choice of statistical methods 
Choice of statistical methods depended on the data available and the purpose of each 
individual study. A time-varying Cox regression model was used in paper I. A Cox 
regression model is suitable for survival data since it can handle censoring.121 With a 
time-varying Cox regression, a variable that was not constant over time could be included 
adequately. Furthermore, a competing risk model was applied to estimate SHR of early 
cancer death. The choice of the competing risk model was based on the concern for deaths 
which were not caused by cancer, even though this was rare. A competing risk model 
allows one to consider the effect of deaths not caused by cancer.103, 122 In a Cox regression 
model individuals dying of other causes would have been censored since the cause of 
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death was not cancer. In the competing risk model, these deaths were included as 
competing events. 
In paper II, SIRs were used which are relatively easy to apply due to their flexibility in the 
calculation of person-time. Furthermore, the results obtained from SIR are also easy to 
understand and can easily be compared to results from other settings.   
In paper III, Cox and logistic regression models were applied. As an alternative to the 
ordinary Cox regression model, a time-varying Cox regression could have been applied to 
facilitate an easier definition of follow-up time. However, a multivariate Cox regression 
model without a time-varying variable was applied and the follow-up time was restricted. 
This model is commonly used and the results could easily be compared to the results from 
other studies.   
Also a linear regression model was applied when studying the delays at attaining a given 
educational level in paper III. Results from the linear regression were only used as part of 
the discussions in both paper III and this thesis. By applying a linear regression model, 
occurrence of delays in educational achievements among the cancer survivors could be 
evaluated and compared to those of the cancer-free population. Results of the linear 
regression model are presented in Appendix II. 
 
5.1.6 Other methodological considerations 
Missing data occurs when no value is recorded for the variable in an observation.123 It has 
been suggested that incompleteness of follow-up may result in overestimations of 
outcomes.124 In paper I, death specification was missing for 48 cancer patients. Given the 
large sample size in our study, it is unlikely to have influenced the results. In Paper III, 
2.8% of the population (similar proportions for the cancer and the cancer-free population) 
lacked educational specifications. Since the proportion of missing values were less than 
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5–10%, deleting the cases was a reasonable solution and there was no need for 
imputation.125, 126 Thus, it is unlikely that removing the individuals with missing 
educational specifications could have influenced the final results and conclusions. 
Grouping of cancer types is a challenge in studies such as the current one with a relatively 
small number of cancer cases. Hence, main categories were studied here.   
In paper I, the cancers were first divided into 11 main categories. Furthermore, the most 
common cancers were studied in detail among young individuals; CNS-tumours (ICD-7; 
193), bone and connective/soft tissue tumours (196–7), lymphomas (206), and leukaemia 
(207). ALL and AML were considered separately. There were very few deaths among HL 
and NHL patients, especially during 1965−1974 and 2005−2009. Hence, HL and NHL 
were not considered separately. Also, Wilms’ tumours could not have been studied 
separately due to the low number of deaths.  
Also in paper II, the main 11 cancer categories were considered. In paper III, the grouping 
of cancers was more challenging. Cancer and its treatments are reported to have a 
significant effect on educational achievements.89, 91 One of the main weaknesses of this 
study was the lack of information on cancer treatment on the individual level. In order to 
account for this, the cancer survivors were divided into the following groups based on the 
general knowledge of cancer treatment in Norway; survivors of CNS-tumours, survivors 
of cancers assumed to have been treated with CNS-directed therapy and all other cancer 
survivors combined. 
 
5.2 Discussion of results 
The risk of early death (paper I) was mainly considered to indicate the efficacy of cancer 
treatment, while uptake of social security benefits and deficits in educational 
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achievements (paper II and III) were considered to be consequences of treatment-induced 
late effects. 
 
5.2.1 Early mortality (paper I) 
In line with other studies,6, 32, 127, 128 the most frequent cancers in our study were CNS-
tumours, leukaemia and lymphoma. In paper I, a general decline in risk of early cancer 
death over time was observed among children, adolescents, and young adults in Norway. 
These findings were in accordance with studies from Europe,7, 8, 32 and the USA.36, 42, 129 
Risk of cancer death decreased substantially among children and adolescents during our 
study period while only a moderate decline was observed among young adults.  
Mortality from childhood leukaemia and other childhood cancers has been reduced 
substantially in western countries in the past few decades.8, 36 A similar trend was 
demonstrated in our study. Other studies reported the highest reduction in mortality for 
leukaemia, lymphoma and brain tumours8, 36, 40, 42. Moderate reduction was reported for 
bone cancers.42 In our study, except AML, early cancer deaths were reduced for the four 
major cancers and all cancers combined. Mortality from AML declined during 
1965−1984 and after 1995; a slight increase during 1985–1994 was observed when 
compared with other diagnosis.  
In our study, trends in mortality among children compared with adolescents and young 
adults were somewhat different from that observed in other studies.31 Adolescents and 
young adults diagnosed with CNS-tumours, bone and connective/soft tissue tumours and 
lymphoma, generally had lower risk of mortality as compared with children, even though 
the differences were not always statistically significant. Results from the US Surveillance, 
Epidemiology, and End Results (SEER) showed that adolescents and young adults with 
ALL had higher mortality than children10 which was similar to our findings. Also, a 
French study on adolescent cancer (age 15–19 years) showed that adolescents when 
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compared with children, had higher mortality from ALL, NHL, osteosarcoma, soft tissue 
sarcoma and Ewing’s tumour.31 Due to the small number of deaths in our study, it was not 
possible to evaluate each of these cancer sites separately and compare them between age 
groups.  
A study from Pritchard-Jones et al.124 on European children (age 0–14 years) and 
adolescents (age 15–19) with cancer showed similar overall 5-year survival among 
adolescents compared with children. In our study, the mortality among adolescents 
compared with children varied by cancer site. Adolescents diagnosed with leukaemia, 
also when ALL and AML were considered separately, had significantly higher risk of 
early death than children. However, adolescents diagnosed with CNS-tumours had 
significantly lower risk of death than children. Those diagnosed with bone and 
soft/connective tissue tumours and lymphoma had similar risk of mortality compared to 
children. Gatta et al.43 studied cancer survival among young individuals in Europe (15–24 
year) diagnosed during 1990–1994. They showed higher mortality among adolescents 
compared with young adults for all cancer sites combined. This was similar to our 
findings (Table 3). The age group variation could be due to differences in the biology of 
cancer, treatment protocols designed for each cancer at each age group, and period of 
diagnosis.  
Another explanation for the lower mortality among adolescents and young adults as 
compared with children might be the presence of a higher proportion of less aggressive 
tumours with more favourable prognosis in adolescents and young adults (such as HL and 
germ-cell tumours) in our study. Categorizing less aggressive tumours into aggressive 
tumour groups or coding benign tumours with malignant cases may also affect the 
mortality rate.124  
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Table 3: Sub-hazard ratios (SHRs) with 95% CI for early cancer death (within 5 years 
after diagnosis) estimated in a multivariate competing risk model for cancer patients 
diagnosed at age 15–24 years during 1990–1994a 
Age at diagnoses All cancer sites combined 
      15–19 1.7 (1.2–2.4) 
      20–24 1 
a Adjusted for gender.  
 
In our study, there was no overlap of outcomes for different age groups over the same 
time period. This issue arises when each age cohort reflects a specific diagnosis period 
and one cannot readily compare all the age groups over similar time periods; thus our 
results represented the net effect of age in the whole study period. An additional sub-
analysis for the diagnostic period 1985–1994 was performed where all the age categories 
were present. The results were similar to our general findings. Adolescents and young 
adults had lower mortality compared with children (Table 4).  
Table 4: Sub-hazard ratios (SHRs) with 95% CI for early cancer death (within 5 years 
after diagnosis) estimated in a multivariate competing risk model for cancer patients 
diagnosed before the age of 25 and during 1985–1994a 
Age at diagnosis All cancer sites combined 
      0–14 1 
      15–19 0.7 (0.6–0.9) 
      20–24 0.4 (0.3–0.6) 
a Adjusted for gender. 
 
Norway has a public health care system where treatments are offered free of charge for 
the Norwegian residents. Thus, cancer patients at all ages receive adequate treatment and 
care appropriate to their diagnoses. This may partly explain the difference in our results 
compared to the research of others from different health care systems. Furthermore, 
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choice of study population, classification criteria, grouping of cancer sites (detailed or 
more general) and/or choice of analytic methods could explain further differences. More 
research is warranted to explore the background for the observed differences in detail.  
 
5.2.2 Social security benefits (paper II) 
Similar to previous research, an increased need for assistance and uptake of social 
security benefits was observed among the cancer survivors compared with the cancer-free 
population. Increased need for supportive measures has previously been shown to be due 
to various late effects.20, 80, 81, 130, 131  
Only a few studies have explored the need for supportive measures such as social security 
benefits among cancer survivors. Studies by Mulrooney et al.60 and Oeffinger et al.18 
explored late effects based on National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCTCAE). Severe late effects were coded as grade 3 and 4 in 
accordance with NCTCAE. Mulrooney et al. reported that approximately 28% of the 
long-term survivors (excluding survivors of AML) compared with 6% of the siblings had 
a severe chronic medical condition. Oeffinger et al. also reported severe and life-
threatening health problems among 27.5% of the cancer survivors compared with 5.2% 
among the siblings. Our results were in line with their findings for severe conditions. The 
study by Thorsen et al.80 from Norway showed the need for at least one rehabilitation 
service among 63% of the individuals. This high percentage compared to our results is 
probably due to the composition of the study population which included all cancer 
individuals aged 25–60 years. It may also indicate that the risk of late effects increases 
further with increasing age. Further research exploring this possibility is therefore 
necessary.  
In line with our findings, a Norwegian study20 on cancer survivors diagnosed during 
1970–1997 (age <15 years) showed that survivors of CNS-tumours more frequently 
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received social security benefits compared with survivors of malignancies of the 
haematopoietic system. Hjern et al.81 explored the effect of cancer and its treatment 
among adult survivors of childhood cancer (diagnosed <16 years). According to their 
findings, survivors of CNS-tumours, leukaemia and lymphoma had a high risk of 
disabilities warranting uptake of benefits. Similar results were observed in our study. 
Hjern et al. also reported that younger age at diagnosis increased the risk of disability. 
Similar to our study, uptake of disability pension was highest among children compared 
to adolescents and young adults (Table 5). Generally, survivors of CNS-tumours and 
leukaemia were reported to have higher incidence of late effects compared to other 
survivors.18, 70, 130-132 This could be due to the intense treatment protocols for these cancers 
as well as the young age at diagnosis. Although younger patients respond better to 
treatment, they are at higher risk of developing late effects. 
Table 5: Standardized incidence ratio (SIR) for diagnoses obtained for disability pension 
from social security benefits available from 1992–2006  
Diagnoses age Cancer cases Cases with disability pension SIR (95% CI) 
      0–4 590 67 6.6 (5.1–8.4) 
      5–9 407 48 6.7 (5.0–8.9) 
      10–14 473 53 6.2 (4.6–8.1) 
 
A Dutch study on childhood cancer survivors showed that autonomy and social and 
psychosexual developments could give an indication for the likelihood of applying for 
disability pension.82 Mental illnesses were reported frequently as one of the causes for 
uptake of disability pension in our study. However, to study the subgroups in more detail 
was not possible due to small number of cases. As mentioned earlier, such studies may be 
necessary on a Nordic level to ensure a larger number of cases. 
Physical performance limitations were reported from other studies.68, 133, 134 A study by 
Ness et al.135 from the US showed that physical performance limitations were more 
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frequently seen among childhood cancer survivors than their siblings and that the 
prevalence may increase with younger diagnosis age. They suggested that poor access to 
health care may be associated with physical disability. This is not applicable to the 
Norwegian population because the health care system is free of charge in Norway. Thus, 
health impairments occurring among cancer patients are mainly due to effects of cancer 
and its treatment on the physical and mental health of the patients. Other studies showed 
increased risk of physical impairments for female survivors, survivors of bone and brain 
tumours and Hodgkin’s disease.27, 134 In our study, female patients had a higher risk of 
attendance benefits and disability pension uptake. Attendance benefits reflect economic 
burdens while disability pension is an indication of reduced working ability. Survivors of 
bone and connective/soft tissue tumours and CNS-tumours had the highest risk of uptake 
when all the different social security benefits were studied combined.  
Other studies have shown increased risks of cardiac dysfunction.136-138 In our study, 
diagnostic groups retrieved from various uptake rates varied, but diseases of the 
circulatory system were not a common cause of social security benefit uptake. One 
problem with using data from NIS is that only individuals with severe conditions may be 
qualified for uptake of social security benefits. As a result, individuals may have impaired 
health conditions, but do not qualify for social security benefits. As such, less pronounced 
but perhaps life inflicting disabilities remain unaccounted for in our study. 
Studies have reported that cancer survivors are more likely to be unemployed,27, 94, 139 
living with their parents140 or be uninsured.83 Follow-up care and screening may be 
expensive and cause a financial burden on cancer survivors and their family. If the health 
care system does not provide such services free of charge, there is a need for health 
insurance coverage which may be costly and/or not extend fully to cover all the various 
health expenses.83 Consequently, cancer survivors may not receive preventive care 
services that may prevent relapse or the occurrence of late effects. Our results indicated 
an increased need for help and care provided by the society among the cancer survivors. 
In Norway, the health care system is public where cancer treatment and follow-up is 
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provided basically free of charge.51 Extra medical costs that are caused by late effects are 
covered by social security benefits.  
Other studies have mostly focused on specific cancer sites, usually brain tumours, 
leukaemia or lymphoma, and fewer possible adverse effects.130, 132, 141-144 In contrast, 
access to registry-based data has enabled us to study various late effects using data 
retrieved from NIS. Although the total numbers of late effects were small, it was possible 
to provide what was considered to be an overall picture of survivors’ health and welfare 
in Norway. 
 
5.2.3 Educational achievements (paper III) 
In line with previous research, some educational deficits were observed among cancer 
survivors compared with the cancer-free population.19, 25, 89, 93 Significant deficits among 
survivors of CNS-tumours and those assumed to have received CNS-directed therapy was 
displayed in our study. Survivors of “Other” cancers had in general similar educational 
achievements compared to the cancer-free population. Some educational deficit at the 
tertiary level was also indicated, but no significant differences in choice of educational 
fields were observed.  
In line with our findings, educational impairments have been reported frequently among 
survivors of CNS-tumours91, 93, 145 and leukaemia.95 Barrera et al.146 studied the 
educational and social outcomes among children diagnosed before age 17. They showed 
that survivors of CNS-tumours, leukaemia and neuroblastoma more often had educational 
problems. Similarly in our study, survivors of CNS-tumours (at all levels of education) 
and those assumed to have received CNS-directed therapy (including survivors of 
leukaemia) had most educational impairments.  
Finnish studies91, 95 showed that foreign language grades of patients with brain tumours 
and leukaemia at the ninth grade were most pronouncedly affected by cancer and its 
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treatment. This effect was especially noted among girls. Foreign language was considered 
as an indication of verbal performances.91 Another Finnish study19 showed impaired 
grades among NHL patients and radiated Wilms’ tumour patients. In our study, in order to 
evaluate differences in various subjects at the intermediate level, pupils’ grades similar to 
that in the Finnish studies should have been accesible.19, 91, 95 Access to data on grades in 
our study could have improved the comparability of our results as well as the possibility 
to evaluate the school performance of pupils at the intermediate level of education in 
more detail.  
A Norwegian cross-sectional study of all young Nordic adult survivors139 reported similar 
rates of high school graduation among cancer survivors compared with controls. In our 
study, only survivors of “Other” cancers had similar educational achievements compared 
to the cancer-free population. Higher frequencies of repeating a grade and higher rates of 
school absence among cancer individuals than of that of the control group have been 
reported from an US study.96 Although similar data on repeats of grades and school 
absence was not available in our study, our results showed that survivors completed each 
level of education less often than the cancer-free population. School absence and 
repeating a grade could be a possible explanation for the delays observed in our study.     
Special education has been examined in other studies,25, 97, 145 and research shows that 
cancer survivors are more often in need of such education. The review by Gurney et al. of 
published studies27 showed that survivors were more often in need of special education 
than the control group. Information on special education was not available in our study. 
Therefore, evaluation of the need for such services among the cancer survivors compared 
with the cancer-free population was not possible. On the other hand, the Norwegian 
education system provides services to pupils with special needs. Therefore, cancer 
survivors in our study are likely to have received special education if considered 
necessary.  
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Differences in educational achievements among the cancer survivors and the cancer-free 
population diminished at higher levels of education in our study. Results from paper I 
and II indicated that children had higher mortality and were in general more likely to 
receive social security benefits than adolescents. This could indicate that healthier 
children survived heavy and aggressive treatments, which may partly explain our results. 
Another possibility could be that cancers with better prognoses were overrepresented, 
especially among those diagnosed between 15–18 years. This could potentially result in 
lower educational differences between the cancer and the cancer-free population.  
To our knowledge, choice of educational field at higher level of education has not been 
studied before. Our results showed no significant differences between cancer survivors 
and the cancer-free population. A possible explanation could be similar educational 
achievements at higher levels of education for the cancer survivors and the cancer-free 
population. Due to relatively small number of survivors, it was not possible to study the 
differences in choice of educational fields in finer groups (i.e. the narrow fields of 
education presented in Appendix I).  
Results from the linear regression model (Appendix II) indicated only minor delays in 
completing a level of education among the 5-year cancer survivors despite their intense 
and prolonged cancer treatments. A lack of delay could partly be explained by 
improvements in awareness in the Norwegian educational system and thus the provision 
of better services for pupils with special needs. As discussed earlier, there is a possibility 
that only patients with less aggressive cancers at the early study period survived, and 
therefore their educational performances were less affected.  
Impact of education on uptake of disability pension among the cancer survivors was 
studied here. Only survivors that were diagnosed before age 22 and reached age 27 were 
included, and the highest obtained level of education was then considered. Survivors with 
university education had a lower risk of disability pension uptake than survivors with 
lower education (Table 6). The results of paper II showed that cancer survivors were more 
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likely to receive social security benefits compared to the cancer-free population. This was 
the case even after adjusting for the effects of education. This could indicate that in spite 
of educational accomplishment, there is a possibility that cancer survivors may not be 
able to use their education for getting desirable jobs or equal earnings compared to the 
cancer-free population. This warrants further research.  
Table 6: Hazard ratios (HRs)a with 95% CI of uptake of disability pension among cancer 
survivors diagnosed before age of 22 years and reached age 27 years by level of 
education 
Level of education HR (95% CI) 
      Compulsory  1 
      Intermediate  0.8 (0.4–1.4) 
      Tertiary 0.2 (0.1–0.5) 
a Adjusted for gender, year of birth and parental education. 
 
Cancers and treatment protocols have significant effect on survivors’ educational 
achievements.19, 91 Although adjustment for potential treatment effects was not possible, 
the general knowledge on cancer treatment protocols applied in Norway during the past 
few decades was used. In our study, significant differences were mostly observed for 
those diagnosed during 1975–1984. These patients were diagnosed at the treatment 
transition period that took place from the 1970s to the 1980s where treatment was fairly 
intense. They may, therefore, have been over-treated; but studying this effect was not 
possible. 
As mentioned earlier, structural changes (such as Reform 94, Reform 97 and Quality 
Reform in 2003) have taken place in the Norwegian educational system during the past 
few decades. Only Reform 94 could have affected our study population. Moreover, most 
observed delays in our study occurred before 1990, and therefore it is unlikely that our 
results have been affected by these changes.  
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6. Conclusion and future perspective 
Access to data from population-based registries gave us a unique opportunity to study the 
impact of cancer on young people in general. Consequently, some important questions 
regarding the individuals’ life prospects after a cancer diagnosis could be clarified.  
Cancer mortality among patients diagnosed before age 25 years in Norway has been 
reduced over time, also relative to the cancer-free population. Consequently, more 
patients survive and become 5-year survivors. Cancer diagnosis and its treatment may 
cause severe late effects among survivors that could appear later in life. Our results 
showed increased rate of social security uptake among 5-year survivors compared with 
the cancer-free population. Uptake of social security benefits was associated with year of 
birth, younger age at primary cancer diagnosis and type of cancer. Survivors of bone and 
connective/soft tissue tumours, CNS-tumours and leukaemia were more likely to be 
recipient of social security benefits. Further follow-up147 and long-term medical 
surveillance of cancer survivors diagnosed in younger years may minimise the occurrence 
of late effects and increase the health awareness among the cancer survivors.148-150  
Lower educational achievements among some groups of cancer survivors were observed 
compared with the cancer-free population. These effects were more pronounced at lower 
levels of education (intermediate level). Although cancer survivors were less likely to 
complete their education at university level, choice of educational fields was similar for 
the cancer and the cancer-free population. Providing supportive educational measures for 
students, especially at lower level of education, may help improving educational 
achievements among the individuals diagnosed with cancer at an early age.  
Further research on cancer and treatment effects is necessary to improve the long-term 
survival rate and reduce the occurrence of late-effects with implications for social security 
uptake and educational attainment. Additionally, providing proper information to the 
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public and health professionals could improve general knowledge about long-term 
consequences and need for proper care for these cancer survivors.134, 147  
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Errata 
Paper I:  
During the work on our project, we discovered a small programming error. A small 
population of children who were not born in Norway, especially during the first two years 
of the study period (1965-1966) was included in the original manuscript. We have 
repeated all analyses in the published paper. Fortunately, only small differences in 
numbers were observed, and all conclusions remained unchanged (Appendix III).  
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Figure 1: Early death rates (5 years after diagnosis) caused by cancer and other causes among cancer patients by age 
at diagnosis (<1, 1−14, 15−19 and 20−24 years) per 1,000 person-years. Note that patients diagnosed in the period 
2005−2009 were at least 20 years of age at the time of diagnosis. The y-axes are presented in logarithmic scale 
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 Table 1: Characteristics of the cancer patients born in Norway during 1965−1985 
 No. of individuals (%) 
Total no. of 
deaths a (%) 
No. of cancer 
deaths (%) 
Gender    
    Male 3,268 (56.3) 889 (59.9) 846 (60.0) 
    Female 2,534 (43.7) 601 (40.1) 563 (40.0) 
    
Year of birth    
    1965-1969 1,504 (25.9) 524 (35.0) 465 (33.0) 
    1970-1974 1,456 (25.1) 413 (27.6) 403 (28.6) 
    1975-1979 1,306 (22.5) 276 (18.4) 264 (18.7) 
    1980-1985 1536 (26.5) 286 (19.1) 277 (19.7) 
    
Age at diagnosis    
    0-14 2,481 (42.8) 1,007 (67.2) 938 (66.6) 
    15-19 1,289 (22.2) 257 (17.1) 249 (17.7) 
    20-24 2,032 (35.0) 235 (15.7) 222 (15.8) 
    
Year of diagnosis     
    1965-1974 534   (9.2) 349 (23.3) 297 (21.1) 
    1975-1984 1,230 (21.2) 474 (31.6) 462 (32.8) 
    1985-1994 2,128 (36.7) 441 (29.4) 423 (30.0) 
    1995-2004 1,639 (28.2) 219 (14.6) 211 (15.0) 
    2005-2009 271 (4.7) 16 (1.1) 16 (1.1) 
    
Cancer site (ICD-7 codes)    
    Kidney (180.0) b 154 (2.7) 43 (2.9) 36 (2.6) 
    Eye (192) 98 (1.7) 7 (0.5) 6 (0.4) 
    CNS tumor (193) 1,192 (20.5) 407 (27.2) 385 (27.3) 
    Thyroid gland and other endocrine glands (194-5) c 370 (6.4) 57 (3.8) 53 (3.8) 
    Bone and connective tissue (196-7) 393 (6.8) 156 (10.4) 154 (10.9) 
    Lymphatic system (206) 742 (12.8) 133 (9) 125 (8.9) 
          Hodgkin lymphoma 414 (55.8) 23 (17.3) 20 (16.0) 
          Non-Hodgkin lymphoma 270 (36.4) 92 (69.2) 88 (70.4) 
          Other 58 (7.8) 18 (13.5) 17 (13.6) 
    Hematopoietic system (207)  1,008 (17.4) 479 (32.0) 454 (32.2) 
          Acute lymphatic leukemia (ALL) 625 (61.9) 217 (45.3) 213 (46.9) 
          Acute myelogenic leukemia (AML) 191 (18.9) 127 (26.5) 121 (26.7) 
          Other 194 (19.2) 135 (28.2) 120 (26.4) 
    Cervix uteri (171) 68 (1.2) 10 (0.7) 10 (0.7) 
    Ovary (175) 100 (1.7) 12 (0.8) 12 (0.9) 
    Testis (178) 741 (12.8) 45 (3.0) 40 (2.8) 
    Melanoma (190) 471 (8.1) 20 (1.3) 18 (1.3) 
    Other 465 (8.0) 130 (8.7) 116 (8.2) 
    
Year of death    
    1969-1974 d  299 (19.9) 248 (17.6) 
    1975-1984  454 (30.3) 442 (31.4) 
    1985-1994  450 (30.0) 437 (31.0) 
    1995-2004  261 (17.4) 248 (17.6) 
    2005-2008  35 (2.3) 34 (2.4) 
Total 5,802 (100.0) 1,499 (100.0) 1,409 (100.0) 
a Death cases within 5 years after diagnosis b 83.8 % were Wilms tumor cases c This site include malignant neoplasm of the thyroid 
gland (44.6%), suprarenal gland (16.8 %), pituitary gland (20.8 %), pineal gland (8.1 %), cranieopharyngeal canal (9.2 %), and others 
(0.6 %) d 48 patients who died before 1969, lack cause of death specification 
 Table 2: Hazard ratios (HRs) of death among the cancer patients diagnosed before age 25 relative to 
individuals without cancer by year of diagnosis, with 95% confidence intervals (CI) estimated by a time-
dependent Cox regression model a 
 
5 years follow-up after diagnosis b 
(n c =1,499/5,802) 
Total follow-up 
(n=1,793/5,802) 
Year of diagnosis d   
      1965-74 361.5 (313.9,416.2) 79.7 (69.8-91.0) 
      1975-84 245.2 (216.8,277.4) 46.2 (41.3,51.5) 
      1985-94 94.1 (83.4,106.1) 28.9 (26.1,32.1) 
      1995-04 41.3 (34.8,49.1) 26.0 (22.1,30.5) 
      2005-09 19.3 (9.2,40.7) 25.4 (12.1,53.4) 
a The analysis was adjusted for gender and year of birth (1965−1969, 1970−1974, 1975−1979 and 1980−1985) b The follow-up time 
was from birth until 5 years after diagnosis c N represents the number of deaths / total number of cancer patients d The analyses were 
performed relative to the general population 
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